Other PRMTs also play immunomodulatory roles: in melanoma, the PRMT4 inhibitor EZF2302 restores sensitivity to anti-CTLA-4 therapy [607], while the PRMT7 inhibitor SGC3027 enhances anti-tumor T cell responses and reduces tumor burden when combined with ICB by promoting immune cell infiltration [460]. Here, CTLA4 is linked to melanoma.